CodeBlue urges Malaysian MPs to vote for tobacco control bill

Jul.18.2022
CodeBlue urges Malaysian MPs to vote for tobacco control bill
Malaysian health NGO, CodeBlue, urges lawmakers to support the Tobacco and Smoking Control Bill to ban cigarettes for those born after 2005.

CodeBlue, a non-profit health organization in Malaysia, is urging lawmakers to vote in support of the "Tobacco and Smoking Control Bill," which would prohibit individuals born after 2005 from purchasing and using cigarettes. Here is the full statement.


The crucial "Tobacco and Smoking Control Act" will be submitted to Parliament this week, which will have an impact on the health and social welfare of our future generations. It is crucial that all members of Parliament fully understand these issues and support this important legislation.


It is important to note that this bill does not restrict smoking among adults, but rather aims to prohibit the sale and use of cigarettes and e-cigarette products to all children born after 2005 (those who will turn 18 in 2023).


Smoking is a rapidly growing epidemic among our children. The 2019 national health and disease rate survey provides us with national data on adolescent smoking behavior. The data is alarming for children aged 15 to 19, as it shows a significant increase in smoking rates.


At present, there are 303,800 smokers, accounting for 11.6% of the population.


A total of 196,000 individuals, which is equivalent to 7.5% of the population, are currently using e-cigarettes.


15.6% of teenagers aged 15 to 19 are currently using tobacco products.


It is anticipated that since the investigation, there has been a significant increase in the number of adolescents who have started using electronic cigarettes in recent years. As pediatricians, we are aware that many young children are drawn to using electronic cigarette products due to their appealing flavors and stylish devices, as well as the desire to appear "cool".


Teenagers smoking electronic cigarettes and becoming addicted can be seen throughout the country. It is widely recognized that most smokers develop their habit in their teens, and smoking e-cigarettes only makes it easier to develop addiction.


Worrying statistics have emerged from the Malaysian National Tobacco and E-cigarette Survey among Youth (TECMA), which shows that 9.1% of Malaysian youths aged 10 to 19 currently use e-cigarettes, with at least 600,000 children included in this group. Among these children, half started using e-cigarettes before the age of 14.


Smoking addiction is extremely difficult to overcome. Some users will gradually turn to more addictive and harmful drugs.


We urge our congressional representatives to consider the health and well-being of all of our children. Please vote in favor of the Tobacco Control Act. The impact of eliminating a major source of social ills and reducing the long-term health problems and death tolls cannot be overstated.


Voting in favor of this bill is a vote in support of investing in the current and future health and well-being of our children.


Voting in favor of the bill represents a vote of hope for all families whose children are no longer addicted to drugs or e-cigarettes.


Voting in favor of the bill is a vote in support of our healthcare system to alleviate the burden of major illnesses.


Dr. Amar-Singh HSS is a pediatric consultant.


Dr. Selva Kumar is a pediatric consultant and the president of the Malaysian Pediatric Association (MPA).


Dr. Musa Mohd Nordin, pediatric consultant.


Dr. Zulkifli Ismail, Pediatric Consultant.


Dr. Thiyagar Nadarajaw is a pediatric consultant and vice president of the Malaysian Adolescent Health Association (MAAH).


Please provide context and the original text to be translated.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
China STMA Deputy Administrator Meets KT&G COO as Heated Cigarette Rules Advance
China STMA Deputy Administrator Meets KT&G COO as Heated Cigarette Rules Advance
Wang Gongcheng, deputy administrator of China’s State Tobacco Monopoly Administration, met KT&G Chief Operating Officer Lee Sang-hak in Shanghai on September 1, according to Oriental Tobacco News. The meeting comes as China seeks public comment on a draft mandatory national standard for heated cigarettes. The report did not disclose the subjects discussed or indicate whether heated tobacco products or market access were addressed.
News
Sep.02
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Philip Morris International has published its first report aligned with the Taskforce on Nature-related Financial Disclosures, bringing its electronics supply chain and the use and end-of-life stages of smoke-free devices and consumables into its nature-related assessment. PMI said its smoke-free business accounted for about 42% of total net revenues in the second quarter of 2026. The report says non-circular electronic products, particularly single-use items, can increase consumption of limited natural resources and also details an IQOS repair pilot. A 2040 circularity scenario tests assumptions including a 50% reduction in product waste-related costs, 10% raw-material savings and a 25% substitution rate for refurbished products versus new products.
Sep.23